Puluo Pharmaceuticals: The CDMO business is gradually entering the harvest period and is expected to lead the company's performance into a new growth stage.

Pharmaceutical company Poluo stated on the interactive platform that its CDMO business is more promising compared to its raw material drug business. On one hand, the raw material drug business is at the bottom of the industry cycle, with performance under pressure year-on-year. On the other hand, the CDMO business is gradually entering the harvest period, and is expected to lead the company's performance into a new growth stage.